Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

A University of Colorado Cancer Center study published in the journal PLoS One finds alterations in expression of genes PIK3R3 and PTEN, more commonly observed in adult tumors, in the rare, young-adult bone cancer Ewing Sarcoma, potentially offering ways to improve therapy.

4 Feb 2015

New study identifies three genes that enable glioblastoma to recur, progress after radiation therapy

A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.

4 Feb 2015

Two new fluorescent dyes may help localize, resect brain tumors

Two new fluorescent dyes attracted to cancer cells may help neurosurgeons more accurately localize and completely resect brain tumors, suggests a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

2 Feb 2015

Mathematical models of cancer behavior offer new insights on tumor growth

Hassan Fathallah-Shaykh, M.D., Ph.D., believes that math can transform medicine, and he has the numbers to prove it.

2 Feb 2015

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials.

20 Jan 2015

Researchers identify new target that could lead to potential therapies for GBM

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute for Molecular Medicine have identified a new protein-protein interaction that could serve as a target for future therapies for the most common form of brain cancer, glioblastoma multiforme (GBM).

14 Jan 2015

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

At the Virginia Tech Carilion Research Institute, three scientists are planning to create a virus capable of destroying brain cancer.

12 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute.

25 Dec 2014

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.

16 Dec 2014

New MIT study implicates RNA-binding proteins in regulation of cancer

A new study from MIT implicates a family of RNA-binding proteins in the regulation of cancer, particularly in a subtype of breast cancer. These proteins, known as Musashi proteins, can force cells into a state associated with increased proliferation.

16 Dec 2014

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma.

12 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

Henry Ford Hospital today announced that it is actively recruiting patients to participate in a clinical trial taking place at the Hermelin Brain Tumor Center which is showing promising results in patients with brain cancer.

8 Dec 2014

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold.

3 Dec 2014

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone.

17 Nov 2014

Study gives a roadmap for future brain cancer vaccines

Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).

14 Nov 2014

Brain Cancer News and Research

Further Reading

Study could lead to potential therapeutic targets to treat Ewing Sarcoma

New study identifies three genes that enable glioblastoma to recur, progress after radiation therapy

Two new fluorescent dyes may help localize, resect brain tumors

Mathematical models of cancer behavior offer new insights on tumor growth

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

Researchers identify new target that could lead to potential therapies for GBM

Virginia Tech scientists plan to design virus to switch wound-healing drug into cancer fighter

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

EnGeneIC closes oversubscribed Series B financing

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

New MIT study implicates RNA-binding proteins in regulation of cancer

Research finding could lead to new therapies for malignant glioma

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Henry Ford Hospital recruits patients to participate in brain cancer clinical trial

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

Study: Chemotherapy following radiation therapy improves survival in adults with low-grade gliomas

Study gives a roadmap for future brain cancer vaccines

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News